Australian Clinical Labs Limited (ASX:ACL)
Australia · Delayed Price · Currency is AUD 2.820
+0.010 (0.36%)
Oct 7, 2026, 4:10 PM AEST
Australian Clinical Labs Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, Australian Clinical Labs stock has a consensus rating of "Hold" and an average price target of $2.79. The average 1-year stock price forecast is 1.06% lower than the current stock price, while the lowest is $2.26 (-19.86%) and the highest is $3.65 (+29.43%).
Price Target: $2.79 (-1.06%)
Analyst Consensus: Hold
Price Target
ChartAnalyst Ratings
The average analyst rating for Australian Clinical Labs stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Mar '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 3 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 6 | 6 | 6 | 6 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 1 | 1 |
| Total | 8 | 8 | 8 | 8 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Maintains $2.40 | Hold | Maintains | $2.40 | -14.89% | Sep 15, 2026 |
| Ord Minnett | Ord Minnett | Hold Maintains $2.60 | Hold | Maintains | $2.60 | -7.80% | Aug 18, 2026 |
Unknown Analyst Macquarie No rating | Macquarie | Hold Maintains $2.70 | Hold | Maintains | $2.70 | -4.26% | Aug 17, 2026 |
| Goldman Sachs | Goldman Sachs | Sell Downgrades $2.25 → $2.08 | Sell | Downgrades | $2.25 → $2.08 | -26.24% | Aug 7, 2026 |
Financial Forecast
Revenue This Year
754.50M
from 736.15M
Increased by 2.49%
Revenue Next Year
784.88M
from 754.50M
Increased by 4.03%
EPS This Year
0.19
from 0.18
Increased by 2.65%
EPS Next Year
0.20
from 0.19
Increased by 8.50%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is AUD.